learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
2 / 2 resultslearn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
5 / 1000+ resultsresearch The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research GTL1 Is Required for a Robust Root Hair Growth Response to Avoid Nutrient Overloading
GTL1 is needed to control root hair growth and prevent problems when there are too many nutrients.
research Network Analysis Reveals Potential Mechanisms That Determine the Cellular Identity of Keratinocytes and Corneal Epithelial Cells Through the Hox/Gtl2-Dio3 miRNA Axis
Hox proteins help maintain keratinocyte identity by regulating miRNA expression.
research Epigenetic Mechanism of Gtl2-miRNAs Causes the Primitive Sheep Characteristics Found in Purebred Merino Sheep
A special gene region controls the re-emergence of a primitive wool type in Merino sheep, improving their wool yield and adaptability.
research Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
Community Join
5 / 351 resultscommunity A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community GT20029 & KX826 Major Updates from Kintor.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
community Breaking hair loss news! GT20029 is a resounding success!
GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.